 CAMBRIDGE, Mass.--BUSINESS WIRE--- AXLA--Axcella Therapeutics Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator EMM compositions, today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the 